Top

Published in:

01-01-2013 | Epidemiology

Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis

Authors: Noel Pabalan, Hamdi Jarjanazi, Hilmi Ozcelik

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Abstract

Inconsistency of reported associations between the Pro919Ser polymorphism in the BRCA1 interacting protein 1 (BRIP1) gene and breast cancer prompted us to undertake a meta-analysis. Although investigated by fewer studies, we have also studied the risk associated with the two additional BRIP1 polymorphisms, C47G and G64A, and breast cancer riskWe conducted searches of the published literature in MEDLINE through PubMed up to October 2012. Individual data on 5,122 cases and 5,735 controls from eight published case–control studies were evaluated for the Pro919Ser polymorphism. Accordingly, C47G and G64A polymorphisms were studied in 1,539 cases and 1,183 controls, and 667 and 782, respectively.In the overall analysis, association was lacking between the Pro919Ser polymorphism and breast cancer risk (odds ratio [OR] 0.98–1.02), materially unchanged when confined to subjects of European ancestry (OR 0.96–1.03) or even in the high-powered studies (OR 0.97–1.03). In the menopausal subgroups, premenopausal women followed the null pattern (OR 0.94–0.98) for the Pro and Ser allele contrasts, but not for the Pro-Ser genotype comparison where significant increased risk was observed (OR 1.39, P = 0.002). The postmenopausal women (>50 years) exhibited a range of pooled effects from protection (OR 0.83, P = 0.11) in the Pro-Ser genotype to slightly increased risk (OR 1.12–1.16, P = 0.28–0.42) in the Pro and Ser allele comparisons. The G64A polymorphism effects were essentially null (OR 0.90–0.98), but C47G was found to confer non-significantly increased risk under all genetic models (OR 1.27–1.40).Upon conclusion, overall summary estimates imply no associations but suggest susceptibility among carriers of the C47G polymorphism and Pro-Ser genotype in premenopausal women. The premenopausal findings and variable outcomes in postmenopausal women require more studies for confirmation.

Cantor SB, Guillemette S (2011) Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. Future oncol 7(2):253–261PubMedCrossRef

Taniguchi T, D’Andrea AD (2006) Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107(11):4223–4233PubMedCrossRef

Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G et al (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group. Nat Genet 37(9):934–935PubMedCrossRef

Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P, Batish SD, Kalb R, Velleuer E, Barral S et al (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37(9):931–933PubMedCrossRef

Easton DF (1999) How many more breast cancer predisposition genes are there? Breast Cancer Res 1(1):14–17PubMedCrossRef

Yu X, Chini CC, He M, Mer G, Chen J (2003) The BRCT domain is a phospho-protein binding domain. Science 302(5645):639–642PubMedCrossRef

Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA et al (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105(1):149–160PubMedCrossRef

Shiozaki EN, Gu L, Yan N, Shi Y (2004) Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. Mol Cell 14(3):405–412PubMedCrossRef

Peng M, Litman R, Jin Z, Fong G, Cantor SB (2006) BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene 25(15):2245–2253PubMedCrossRef

10.

Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11):1239–1241PubMedCrossRef

11.

Huo X, Lu C, Huang X, Hu Z, Jin G, Ma H, Wang X, Qin J, Wang X, Shen H et al (2009) Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women. J Cancer Res Clin Oncol 135(11):1569–1575PubMedCrossRef

12.

Vahteristo P, Yliannala K, Tamminen A, Eerola H, Blomqvist C, Nevanlinna H (2006) BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer 6:19PubMedCrossRef

13.

Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, Struewing JP (2004) Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer 4:9PubMedCrossRef

14.

Song H, Ramus SJ, Kjaer SK, Hogdall E, Dicioccio RA, Whittemore AS, McGuire V, Hogdall C, Jacobs IJ, Easton DF et al (2007) Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS ONE 2(3):e268PubMedCrossRef

15.

Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH et al (2009) Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 115(1):51–55PubMedCrossRef

16.

Guenard F, Labrie Y, Ouellette G, Joly BC, Simard J, Durocher F (2008) Mutational analysis of the breast cancer susceptibility gene BRIP1/BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. J Hum Genet 53(7):579–591PubMedCrossRef

17.

Rutter JL, Smith AM, Davila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J et al (2003) Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Hum Mutat 22(2):121–128PubMedCrossRef

18.

Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Bianchi S, Palli D, Ottini L (2011) Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy. Breast Cancer Res Treat 126(2):539–543PubMedCrossRef

19.

Frank B, Hemminki K, Meindl A, Wappenschmidt B, Sutter C, Kiechle M, Bugert P, Schmutzler RK, Bartram CR, Burwinkel B (2007) BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study. BMC Cancer 7:83PubMedCrossRef

20.

Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3(3):e42PubMedCrossRef

21.

Garcia-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dabrowska N et al (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 119(4):376–388PubMedCrossRef

22.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed

23.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRef

24.

Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820–826PubMed

25.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560PubMedCrossRef

26.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558PubMedCrossRef

27.

Ioannidis JP, Trikalinos TA (2007) The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 176(8):1091–1096PubMedCrossRef

Title: Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis
Authors: Noel Pabalan
Hamdi Jarjanazi
Hilmi Ozcelik
Publication date: 01-01-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2364-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population

Pain in long-term breast cancer survivors: the role of body mass index, physical activity, and sedentary behavior

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

Comments on the use of a single or multiple probe-set approach for microarray-based analyses of routine molecular markers in breast cancer

Unincluded subjects need to be included for concerning the real association between TNFa−308 G/A polymorphism and cancer susceptibility

Keynote webinar | Spotlight on antibody–drug conjugates in cancer